Pharmacodynamics and Toxicology of Fenflumizole, a New Non‐steroidal Anti‐inflammatory Imidazole Derivative

Publisher Website
Google Scholar
Abstract
Fenflumizole, (2-(2,4-difluorophenyl)-4,5-bis(4-methoxyphenyl) imidazole), a new non-steroidal antiinflammatory agent, was investigated for antiinflammatory, analgesic and anti-pyretic activity in experimental animals. Comparison was made to other non-steroidal antiphlogistics. General pharmacodynamics and toxicity of fenflumizole was studied. Fenflumizole was comparable to or weaker than indomethacin in models of acute inflammation (carrageenan paw edema and pleurisy, rats, UV erythema, guinea pigs) and stronger than indomethacin as an analgesic (writhing, mice). As an antipyretic agent (arachidonic acid pyresis, rats) fenflumizole was 3 times weaker than indomethacin. The acute gastroulcerogenicity and toxicity of fenflumizole was low as compared to reference drugs. No untoward activity of fenflumizole on respiratory and circulatory systems was observed in rabbits and dogs. Fenflumizole is a potential new therapeutic agent with antiinflammatory, analgesic and anti-pyretic activities comparable to other antiphlogistics but with reduced side effects.